Sigyn Therapeutics

Treating Infectious Diseases That Drugs Can't

About this Event

Sigyn Therapeutics, Inc. [OTCQB: SIGY] is a pioneering developer of medical devices targeting cancer, dialysis, organ transplantation, and infectious diseases that are untreatable with drugs. Led by an experienced team with first-in-industry achievements, Sigyn’s breakthrough technologies have the potential to significantly impact several severe medical conditions that have limited pharmaceutical solutions.

Key Highlights:
  • Infectious Disease Solutions: Sigyn Therapy is a novel blood purification technology that effectively removes viral pathogens, bacterial toxins, and inflammatory cytokines from the bloodstream, addressing key global health challenges like antibiotic resistance and sepsis.
  • Cancer Treatment Enhancement: Sigyn’s ImmunePrep, ChemoPrep, and ChemoPure platforms are designed to improve cancer therapy outcomes by enhancing delivery and reducing toxicity of immunotherapies and chemotherapies.
  • Organ Transplantation Potential: Sigyn Therapy is being studied for its ability to reduce pathogen transmission risks in organ transplants.
  • End-stage Renal Disease Treatment: Sigyn Therapy has the potential to treat endotoxemia and concurrent inflammation, extending the lives of 550,000 individuals who suffer from ESRD in the United States.

With FDA guidance supporting these advancements, Sigyn’s innovative solutions offer significant potential value across the pharmaceutical, dialysis, and organ transplant sectors.

Sign up to watch this online event with Sigyn Founder and CEO, Jim Joyce, as he shares the details of their innovative device and its potential to transform the lives of millions of patients.

Video On Demand

– Recorded

December 4

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.